Literature DB >> 10866081

Dynamic MR imaging of liver metastases with Gd-EOB-DTPA.

W Stern1, F Schick, A F Kopp, P Reimer, K Shamsi, C D Claussen, M Laniado.   

Abstract

PURPOSE: To assess liver and lesion enhancements by dynamic MR imaging after bolus injection of the hepatobiliary contrast agent gadolinium ethoxybenzyl-diethylenetriamine-pentaacetic acid (Gd-EOB-DTPA) in patients with liver metastases and to compare the effect of different doses.
MATERIAL AND METHODS: A randomized double-blinded trial with doses of 12.5, 25 and 50 micromol/kg Gd-EOB-DTPA was performed in 35 patients with liver metastases. Liver enhancement, tumor enhancement and liver lesion contrast-to-noise (C/N) ratios were calculated from breath-hold gradient echo images (100/5/80 degrees) recorded precontrast and at different times up to 10 min postcontrast.
RESULTS: Normal liver showed a characteristic enhancement pattern, with a rapid enhancement in the first 45 s postcontrast and a slight but significant further increase up to 600 s. The initial enhancement in the lesions was also pronounced, but the enhancement was slightly decreased after 240 s postcontrast. At dose levels of 12.5 and 25 micromol/kg Gd-EOB-DTPA, C/N ratios significantly increased compared to baseline from 90 to 600 s. Postcontrast C/N-values obtained using 50 micromol/kg Gd-EOB-DTPA were not significantly increased, except for the examinations 480 s postcontrast.
CONCLUSION: In liver metastases, C/N ratios obtained with doses of 12.5 and 25 micromol/kg Gd-EOB-DTPA were slightly superior to 50 micromol/kg Gd-EOB-DTPA. This finding is probably due to a more pronounced extracellular effect of the contrast medium at higher doses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10866081     DOI: 10.1080/028418500127345208

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  15 in total

Review 1.  [Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA].

Authors:  C Stroszczynski; G Gaffke; M Gnauck; F Streitparth; G Wieners; E Lopez-Häninnen
Journal:  Radiologe       Date:  2004-12       Impact factor: 0.635

Review 2.  Safety of MR liver specific contrast media.

Authors:  Marie-France Bellin; Judith A W Webb; Aart J Van Der Molen; Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

3.  Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients.

Authors:  Bang-Bin Chen; Chao-Yu Hsu; Chih-Wei Yu; Shwu-Yuan Wei; Jia-Horng Kao; Hsuan-Shu Lee; Tiffany Ting-Fang Shih
Journal:  Eur Radiol       Date:  2011-08-31       Impact factor: 5.315

4.  Gd-EOB-DTPA-enhanced 3.0 T MR imaging: quantitative and qualitative comparison of hepatocyte-phase images obtained 10 min and 20 min after injection for the detection of liver metastases from colorectal carcinoma.

Authors:  Keitaro Sofue; Masakatsu Tsurusaki; Hiroyuki Tokue; Yasuaki Arai; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2011-07-12       Impact factor: 5.315

5.  Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging.

Authors:  D Löwenthal; M Zeile; W Y Lim; C Wybranski; F Fischbach; G Wieners; M Pech; S Kropf; J Ricke; O Dudeck
Journal:  Eur Radiol       Date:  2010-10-02       Impact factor: 5.315

6.  Correlation of liver parenchymal gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid enhancement and liver function in humans with hepatocellular carcinoma.

Authors:  Kei Kubota; Taiji Tamura; Nobutaka Aoyama; Munenobu Nogami; Norihiko Hamada; Akihito Nishioka; Yasuhiro Ogawa
Journal:  Oncol Lett       Date:  2012-03-01       Impact factor: 2.967

Review 7.  Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions.

Authors:  Ahmed Ba-Ssalamah; Martin Uffmann; Sanjai Saini; Nina Bastati; Christian Herold; Wolfgang Schima
Journal:  Eur Radiol       Date:  2008-09-23       Impact factor: 5.315

8.  Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time?

Authors:  Utaroh Motosugi; Tomoaki Ichikawa; Licht Tominaga; Hironobu Sou; Katsuhiro Sano; Shintaro Ichikawa; Tsutomu Araki
Journal:  Eur Radiol       Date:  2009-05-27       Impact factor: 5.315

9.  Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions.

Authors:  Renate Hammerstingl; Alexander Huppertz; Josy Breuer; Thomas Balzer; Anthony Blakeborough; Rick Carter; Lluis Castells Fusté; Gertraud Heinz-Peer; Werner Judmaier; Michael Laniado; Riccardo M Manfredi; Didier G Mathieu; Dieter Müller; Koenraad Mortelè; Peter Reimer; Maximilian F Reiser; Philip J Robinson; Kohkan Shamsi; Michael Strotzer; Matthias Taupitz; Bernd Tombach; Gianluca Valeri; Bernhard E van Beers; Thomas J Vogl
Journal:  Eur Radiol       Date:  2007-12-06       Impact factor: 5.315

Review 10.  Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Authors:  Peter Reimer; Günter Schneider; Wolfgang Schima
Journal:  Eur Radiol       Date:  2004-02-25       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.